標(biāo)題: Titlebook: Inflammation, Infection, and Microbiome in Cancers; Evidence, Mechanisms Jun Sun Book 2021 The American Physiological Society 2021 Cancer p [打印本頁] 作者: TEMPO 時(shí)間: 2025-3-21 17:36
書目名稱Inflammation, Infection, and Microbiome in Cancers影響因子(影響力)
書目名稱Inflammation, Infection, and Microbiome in Cancers影響因子(影響力)學(xué)科排名
書目名稱Inflammation, Infection, and Microbiome in Cancers網(wǎng)絡(luò)公開度
書目名稱Inflammation, Infection, and Microbiome in Cancers網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Inflammation, Infection, and Microbiome in Cancers被引頻次
書目名稱Inflammation, Infection, and Microbiome in Cancers被引頻次學(xué)科排名
書目名稱Inflammation, Infection, and Microbiome in Cancers年度引用
書目名稱Inflammation, Infection, and Microbiome in Cancers年度引用學(xué)科排名
書目名稱Inflammation, Infection, and Microbiome in Cancers讀者反饋
書目名稱Inflammation, Infection, and Microbiome in Cancers讀者反饋學(xué)科排名
作者: 誘騙 時(shí)間: 2025-3-21 22:05
Commensal Microbes and Their Metabolites: Influence on Host Pathways in Health and Cancer,tabolic process. In this chapter, we have discussed the major microbial metabolites that dominate the metabolic landscape of gut microbiota (the cancer microbiome) and influence cancer pathogenesis and chemotherapeutic efficacy.作者: Amplify 時(shí)間: 2025-3-22 02:17
Mitochondrial Regulation of Inflammation in Cancer,ival of tumor cells. Current pharmacological agents seek to exploit this process by targeting either the mitochondria or downstream targets of the mitochondria which promote inflammation. This chapter delves into the origins of mitochondrial dysfunction and the corresponding signaling pathways that regulate inflammation in cancer.作者: 颶風(fēng) 時(shí)間: 2025-3-22 07:33 作者: 疼死我了 時(shí)間: 2025-3-22 09:48 作者: AXIOM 時(shí)間: 2025-3-22 16:37
Biomarkers of Esophageal Cancers and Precancerous Lesions,ncer and precancerous lesions that have already been in clinical application as well as those that are in different stages of discovery and validation. In addition, we briefly introduce the microbiome and other less conventional biomarkers of esophageal cancers.作者: 全神貫注于 時(shí)間: 2025-3-22 17:44
Epithelial and Immune Cell Responses to , That Shape the Gastric Tumor Microenvironment,y response to . infection and immune cell-epithelial crosstalk. The review focuses on reporting the mechanisms by which the bacterium modulates the host’s innate and adaptive immune response and the gastric epithelium as part of a strategy to create an immunosuppressive microenvironment that ultimately leads to gastric cancer.作者: TAIN 時(shí)間: 2025-3-22 23:36 作者: Largess 時(shí)間: 2025-3-23 03:40
Autophagy and Cancer: Current Biology and Drug Development,lective autophagy of mitochondria, called mitophagy, in tumorigenesis. Understanding the roles of autophagy and mitophagy in cancer stem cells, cancer immunosurveillance, cancer metabolism, and iron homeostasis will influence development of emerging anti-cancer therapeutics targeting autophagy.作者: 窗簾等 時(shí)間: 2025-3-23 05:34 作者: frugal 時(shí)間: 2025-3-23 11:28
The Microbiome and Urologic Cancers,ributes to the process of carcinogenesis through metabolic toxification and detoxification as well as immune interactions. The emerging clinical evidence also suggests a prominent role for microbiota in affecting the efficacy of cancer therapeutics, including chemotherapy and immunotherapy agents.作者: 慢慢流出 時(shí)間: 2025-3-23 14:28 作者: BARB 時(shí)間: 2025-3-23 19:05 作者: Harridan 時(shí)間: 2025-3-24 00:06
Olabisi Oluwabukola Coker,Jun Yu) and medical device sectors, the vast majority of testing and evaluation of products is not performed within innovator companies, but rather has been outsourced to a growing universe of commercial organizations. The authors both have more than 30 years experience in this field, and both have worked作者: 仇恨 時(shí)間: 2025-3-24 05:46 作者: COMMA 時(shí)間: 2025-3-24 09:32
Ikuko Kato,Jun Sunthe many new laws, regulations and the new REACH program gov.The last 10 years have seen a seismic shift in therapeutic product development and testing. In both the pharmaceutical (both small and large molecule) and medical device sectors, the vast majority of testing and evaluation of products is n作者: 吹氣 時(shí)間: 2025-3-24 13:22
Manisha Bajpai,Zhongren (David) Zhou) and medical device sectors, the vast majority of testing and evaluation of products is not performed within innovator companies, but rather has been outsourced to a growing universe of commercial organizations. The authors both have more than 30 years experience in this field, and both have worked作者: Intruder 時(shí)間: 2025-3-24 17:21
Meaghan Torvund,Jayati Chakrabarti,Yana Zavros) and medical device sectors, the vast majority of testing and evaluation of products is not performed within innovator companies, but rather has been outsourced to a growing universe of commercial organizations. The authors both have more than 30 years experience in this field, and both have worked作者: Moderate 時(shí)間: 2025-3-24 22:01 作者: 一加就噴出 時(shí)間: 2025-3-25 00:16
Mithunah Krishnamoorthy,Saman Maleki Vareki,Jeremy P. Burton) and medical device sectors, the vast majority of testing and evaluation of products is not performed within innovator companies, but rather has been outsourced to a growing universe of commercial organizations. The authors both have more than 30 years experience in this field, and both have worked作者: cardiopulmonary 時(shí)間: 2025-3-25 05:16 作者: SPURN 時(shí)間: 2025-3-25 11:23 作者: FLAT 時(shí)間: 2025-3-25 14:01
Xiaotao Zhang,Carrie R. Danielion in the United States alone, $64 billion in the European Community, and $45 billion in Japan; in 1998 the US medical equipment trade surplus was $18.2 billion. Between 87,000 and 140,000 different devices are produced in the United States annually by approximately 8200 different manufacturers emp作者: 脫水 時(shí)間: 2025-3-25 19:50
Arianne L. Theissills a void in the literature by closely combining contract theoretical approaches with wireless networks design problems. Topics covered include classification in contract theory, reward design, adverse selection, and moral hazard. The authors also explore incentive mechanisms for device-to-device 作者: 受辱 時(shí)間: 2025-3-25 22:24 作者: TRUST 時(shí)間: 2025-3-26 01:01 作者: 責(zé)怪 時(shí)間: 2025-3-26 07:55
Derek Reiman,Ulises Sosa,Yang Daia 55:303–328,1987) is the first to use a continuous-time model, showing that doing that can, in fact, lead to simple, while realistic optimal contracts. In particular, if the principal and the agent maximize expected utility from terminal output value, and have non-separable cost of effort and expon作者: 繞著哥哥問 時(shí)間: 2025-3-26 11:58
Yinglin Xiaa 55:303–328,1987) is the first to use a continuous-time model, showing that doing that can, in fact, lead to simple, while realistic optimal contracts. In particular, if the principal and the agent maximize expected utility from terminal output value, and have non-separable cost of effort and expon作者: 青春期 時(shí)間: 2025-3-26 16:08
Microbiome and the Hallmarks of Cancer,ents were initially associated with carcinogenesis, technological advances have broadened our knowledge of microbial communities that may impact carcinogenesis, namely, the trillions of microorganisms that live in symbiosis with humans. Commensal microbes (microbiota) live in close association with 作者: absorbed 時(shí)間: 2025-3-26 17:40 作者: OUTRE 時(shí)間: 2025-3-27 00:12 作者: Axillary 時(shí)間: 2025-3-27 02:33 作者: 有限 時(shí)間: 2025-3-27 07:58 作者: FECK 時(shí)間: 2025-3-27 12:04
Epithelial and Immune Cell Responses to , That Shape the Gastric Tumor Microenvironment,er in the United States is relatively low due to the diagnosis and treatment of the major risk factor . (.). Even after . infection has been eradicated, there is still a risk of developing gastric cancer. Gastric cancer is the final clinical outcome that is often initiated by a sustained inflammator作者: Consequence 時(shí)間: 2025-3-27 15:48 作者: compel 時(shí)間: 2025-3-27 21:22 作者: catagen 時(shí)間: 2025-3-27 21:56
Commensal Microbes and Their Metabolites: Influence on Host Pathways in Health and Cancer,sition, with expectation of adverse outcome) in disease, infection, and chronic metabolic disorders are associated with distinct comorbidities, hitherto known, and yet poorly understood. With extensive use of sequence-based molecular phylogeny, we now understand the commensal microbial association w作者: 污穢 時(shí)間: 2025-3-28 02:52
Diet, Microbiome, Inflammation, and Cancer,to recent reviews focusing on the experimental evidence and the potential mechanisms underlying these relationships, this book chapter focuses on human observational and interventional studies of the microbiome as it relates to dietary patterns and key dietary factors with established links to infla作者: 卵石 時(shí)間: 2025-3-28 09:52 作者: defenses 時(shí)間: 2025-3-28 12:16 作者: jaundiced 時(shí)間: 2025-3-28 17:21 作者: angiography 時(shí)間: 2025-3-28 22:12
Machine Learning in Identification of Disease-Associated Microbiota,ssociations can rely on statistical analyses identifying differentially abundant taxa between diseased and healthy populations. Accurate prediction of the host phenotype from a metagenomic sample and identification of the associated microbial markers are important in understanding potential host-mic作者: plasma-cells 時(shí)間: 2025-3-29 00:08
Mediation Analysis of Microbiome Data and Detection of Causality in Microbiome Studies,and complicated. Three general hypotheses have been developed to detect these interactions. Among these hypotheses, testing the mediated effects of environmental factors and host mediated by microbiome is the most often designed, because mediation analysis of the human microbiome in these dynamic an作者: inferno 時(shí)間: 2025-3-29 05:32 作者: 用不完 時(shí)間: 2025-3-29 08:00 作者: nonsensical 時(shí)間: 2025-3-29 14:04
Physiology in Health and Diseasehttp://image.papertrans.cn/i/image/464693.jpg作者: 不可思議 時(shí)間: 2025-3-29 17:40
978-3-030-67953-8The American Physiological Society 2021作者: 牙齒 時(shí)間: 2025-3-29 20:47 作者: BORE 時(shí)間: 2025-3-30 02:34 作者: scrutiny 時(shí)間: 2025-3-30 07:02
Rachel M. Bleich,Janelle C. Arthurct the best possible candidate compound, device or formulation and then moving the resulting regulated therapeutic medical product into and through the development process and to marketing approval. But also co978-1-4899-9890-3978-1-4614-0049-3作者: 杠桿支點(diǎn) 時(shí)間: 2025-3-30 10:58 作者: 錢財(cái) 時(shí)間: 2025-3-30 14:20
Ikuko Kato,Jun Sunct the best possible candidate compound, device or formulation and then moving the resulting regulated therapeutic medical product into and through the development process and to marketing approval. But also co978-1-4899-9890-3978-1-4614-0049-3
